跳至主要内容
临床试验/NCT00372632
NCT00372632已完成4 期

Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in Different Zones of Drug Resistance in Rwanda

Institute of Tropical Medicine, Belgium1 个研究点 分布在 1 个国家目标入组 1,717 人开始时间: 2005年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
1,717
试验地点
1
主要终点
malaria infection will be defined as the presence of asexual stage parasites on thick smears made with maternal side placental blood and Maternal peripheral blood

研究概览

简要总结

The present study will address the question whether the use of IPT using SP in pregnancy is efficacious in Rwanda, where it is going to be used for the first time, in areas with high levels of SP resistance. While the implementation of the new policy will take place in areas at low SP resistance level, where we expect pregnant women and newborns to benefit from it, it is of paramount importance to clarify which is the real impact of IPT/SPin areas of high SP drug resistance and at what level of SP resistance this strategy is still efficacious. As bed nets are a part of the actual control strategy of malaria in pregnancy all women will receive a bed net at enrolment

详细描述

The present study will address the question whether the use of IPT using SP in pregnancy is efficacious in Rwanda, where it is going to be used for the first time, in areas with high levels of SP resistance. While the implementation of the new policy will take place in areas at low SP resistance level, where we expect pregnant women and newborns to benefit from it, it is of paramount importance to clarify which is the real impact of IPT/SPin areas of high SP drug resistance and at what level of SP resistance this strategy is still efficacious. As bed nets are a part of the actual control strategy of malaria in pregnancy all women will receive a bed net at enrolment.

This will be a randomized blinded placebo controlled trial: women in the 16-28th week of gestation will be offered enrolment into the study and randomized to receive IPT/SP regimen or placebo once during the second and once in the third trimesters.

The study will be conducted in Mashesha (estimated SP drug resistance 20%, 12% in 2000), Kicukiro (40% SP resistance) and Rukara (60% SP resistance). In each of these sites there are about 1000 deliveries per year. According to DHMT data, over 75% of pregnant women attend antenatal clinics, usually booking between 15 and 25 weeks of gestation. Based on this study we expect to find placental malaria prevalence over 50% in all sites.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
21 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant women between 16-28 weeks of gestation;
  • Residence within the catchment's area of the health facility;
  • Willing to deliver at the health facility;
  • Willing to ; adhere to all requirements of the study;
  • Willing to provide written informed consent;
  • Aged 21 years and above

排除标准

  • Severe anemia (Hb < 6 g/dL)
  • History of allergic reactions to sulfa drugs;
  • Taking other sulfa drugs as CTX;
  • History of known pregnancy complications (e.g. breech presentation, severe pre-eclampsia, prior caesarian section);
  • History or presence of major illnesses likely to influence pregnancy outcome including diabetes mellitus, severe renal or heart disease, or active tuberculosis, prior to randomization;
  • Any significant illness that requires hospitalization;
  • Intent to move out of the study catchment's area before delivery or deliver at relative's home out of the catchment's area;
  • Prior enrollment in the study or concurrent enrollment in another study

研究组 & 干预措施

placebo

Placebo Comparator

干预措施: placebo (Drug)

sulfadoxine-pyrimethamine

Experimental

干预措施: Sulfadoxine-Pyrimethamine (Drug)

结局指标

主要结局

malaria infection will be defined as the presence of asexual stage parasites on thick smears made with maternal side placental blood and Maternal peripheral blood

时间窗: maternal placental blood at delivery; maternal peripheral blood at monthly visits between 16 weeks of gestation and delivery

次要结局

  • LBW = birth weight <2,500 grams(at delivery)
  • Premature delivery = delivery prior to 37 weeks gestation(at delivery)
  • Spontaneous miscarriage = any spontaneous abortion before the end of gestation(at delivery)
  • Stillbirth(at delivery)
  • Cord blood parasitaemia = presence of asexual stage parasites in thick smears(at delivery)
  • Neonatal death = infant death within the first 28 days of life(7days and 6 weeks after delivery)
  • Maternal anemia = Hb <11.0 g/dL(at monthly visits between 16 weeks of gestation and delivery)
  • Maternal severe anemia = Hb <6 g/dL(at monthly visits between 16 weeks of gestation and delivery)
  • Symptomatic maternal malaria infection = axillary temperature 37.5°C and asexual parasitaemia(at monthly visits between 16 weeks of gestation and delivery)
  • Severe maternal adverse reactions to SP = severe cutaneous reactions (e.g., erythema multiform, Stevens-Johnson syndrome, or toxic epidermal necrolysis)(at monthly visits between 16 weeks of gestation and delivery plus at day 7 and week 6 after delivery)

研究者

发起方
Institute of Tropical Medicine, Belgium
申办方类型
Other

研究点 (1)

Loading locations...

相似试验